GB2220549B - Interleukin-2(il-2) levels as indicators eg,of allograft rejection,or of the presence or beneficial therapy of treatment for infections or autoimmune diseases - Google Patents

Interleukin-2(il-2) levels as indicators eg,of allograft rejection,or of the presence or beneficial therapy of treatment for infections or autoimmune diseases

Info

Publication number
GB2220549B
GB2220549B GB8908920A GB8908920A GB2220549B GB 2220549 B GB2220549 B GB 2220549B GB 8908920 A GB8908920 A GB 8908920A GB 8908920 A GB8908920 A GB 8908920A GB 2220549 B GB2220549 B GB 2220549B
Authority
GB
United Kingdom
Prior art keywords
interleukin
infections
indicators
levels
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB8908920A
Other versions
GB2220549A (en
GB8908920D0 (en
Inventor
Andrew J Cornaby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Endogen Inc
Original Assignee
Genzyme Corp
Endogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Endogen Inc filed Critical Genzyme Corp
Publication of GB8908920D0 publication Critical patent/GB8908920D0/en
Publication of GB2220549A publication Critical patent/GB2220549A/en
Application granted granted Critical
Publication of GB2220549B publication Critical patent/GB2220549B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB8908920A 1987-08-21 1988-08-19 Interleukin-2(il-2) levels as indicators eg,of allograft rejection,or of the presence or beneficial therapy of treatment for infections or autoimmune diseases Expired - Fee Related GB2220549B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8775987A 1987-08-21 1987-08-21
PCT/US1988/002866 WO1989001627A1 (en) 1987-08-21 1988-08-19 Elevated il-2 levels as indicators e.g., of allograft rejection

Publications (3)

Publication Number Publication Date
GB8908920D0 GB8908920D0 (en) 1989-09-20
GB2220549A GB2220549A (en) 1990-01-17
GB2220549B true GB2220549B (en) 1991-07-24

Family

ID=22207080

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8908920A Expired - Fee Related GB2220549B (en) 1987-08-21 1988-08-19 Interleukin-2(il-2) levels as indicators eg,of allograft rejection,or of the presence or beneficial therapy of treatment for infections or autoimmune diseases

Country Status (8)

Country Link
EP (1) EP0329773A4 (en)
JP (1) JPH02500617A (en)
AU (1) AU2423288A (en)
CA (1) CA1335564C (en)
DK (1) DK192689A (en)
FI (1) FI891889A (en)
GB (1) GB2220549B (en)
WO (1) WO1989001627A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772572A (en) * 1982-08-28 1988-09-20 Ajinomoto Co., Inc. Hybridomas and monoclonal antibodies to human IL-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111344A2 (en) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Anti-interleukin-2 monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772572A (en) * 1982-08-28 1988-09-20 Ajinomoto Co., Inc. Hybridomas and monoclonal antibodies to human IL-2

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. Immunopharmacology 1985, 7(3), 267-284 *
J. Immunopharmacology 1986, 8(3), 427-435 *
J.W.Kimball, Introduction to Immunology, 1983, (MacMillan), pages 215, 221, 475, 476. *
Scand. J. Immunol. 1987, 25, 101-106 *

Also Published As

Publication number Publication date
DK192689D0 (en) 1989-04-20
EP0329773A1 (en) 1989-08-30
WO1989001627A1 (en) 1989-02-23
GB2220549A (en) 1990-01-17
AU2423288A (en) 1989-03-09
JPH02500617A (en) 1990-03-01
FI891889A0 (en) 1989-04-20
GB8908920D0 (en) 1989-09-20
CA1335564C (en) 1995-05-16
FI891889A (en) 1989-04-20
EP0329773A4 (en) 1991-04-17
DK192689A (en) 1989-06-20

Similar Documents

Publication Publication Date Title
EG18268A (en) Medicament for the treatment of inflammation of the eye
OA08581A (en) Treatment of diseases caused by retroviruses.
GB8607035D0 (en) Crop treatment processes
HU886792D0 (en) Device for the drawing of blood for single use
DE3472210D1 (en) Neodym-yag-laser, particularly for ophthalmological treatment
NO880292D0 (en) PROCEDURE FOR HUMAN TREATMENT.
GB2220549B (en) Interleukin-2(il-2) levels as indicators eg,of allograft rejection,or of the presence or beneficial therapy of treatment for infections or autoimmune diseases
DE3174448D1 (en) Combinations for the treatment of wounds
GB8714972D0 (en) Medical treatment
IL89204A0 (en) Veterinary composition,especially suitable for the treatment of mastitis
GB8721310D0 (en) Effluent treatment
EP0248361A3 (en) Pharmaceutical preparation for the treatment of bacterial infections
GR3005231T3 (en)
JPS56125055A (en) Medical treatment member
GR3000306T3 (en) Composition for the treatment of infections
ZA832004B (en) Retainer for sterile surgical products
ZA877303B (en) Pharmaceutical composition for the treatment of high blood pressure
IT1216059B (en) PROCEDURE FOR THE SEPARATION OF MACROCYCLIC DIASTEREOMERS.
EP0412938A3 (en) System for the treatment of contactlenses
DE3366025D1 (en) Medicine for the treatment of the neoplazic disease
AU1705783A (en) Medicine for the treatment of the neoplazic disease
JPS5660551A (en) Shadeless lighting system for medical treatment
GB2185477B (en) Novel bicyclic lactam, pharmacologically active compositions thereof, processes for the preparation thereof and their medical use
JPS55129066A (en) Purifier for medical treatment
IL56551A0 (en) Sterilized lubrication means for medical or other uses

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19950819